Evaluating Ovid Therapeutics: Insights From 6 Financial Analysts
Portfolio Pulse from Benzinga Insights
Ovid Therapeutics (NASDAQ:OVID) has received mixed ratings from 6 analysts, with a majority being bullish. The average 12-month price target is $6.92, down from $7.33. Analysts have adjusted their ratings and price targets in response to market conditions and company performance. Ovid Therapeutics has shown strong revenue growth but struggles with profitability.
June 18, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ovid Therapeutics has received mixed ratings from analysts, with a majority being bullish. The average 12-month price target is $6.92, down from $7.33. The company has shown strong revenue growth but faces challenges in profitability.
The mixed ratings and lowered price targets indicate uncertainty among analysts. While the company shows strong revenue growth, its significant net margin challenges and recent price target reductions suggest a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100